Table 2.
Apolar metabolites significantly affected by TCDD (p < 0.01) and average fold change ratio between treatments (TCDD vs. DMSO).
| GC-MS | Ratio TCDD/DMSO (RTD) |
|---|---|
| C12:0 | 0.78 |
| C14:0 | 0.72 |
| C14:1a | 0.70 |
| C14:1b | 0.29 |
| C16:1 (n-6) | 0.63 |
| C16:1 (n-9) | 0.62 |
| C17:0 | 1.20 |
| C18:0 | 1.27 |
| C18:1 (n-9) | 0.78 |
| C18:1c | 0.72 |
| C18:2a | 0.71 |
| C18:2b | 0.63 |
| C18:2c | 1.29 |
| C18:2d | 0.64 |
| C18:2e | 0.63 |
| C20:1b | 0.79 |
| C20:2a | 0.74 |
| C20:2b | 0.70 |
| C20:3a | 0.80 |
| C20:3b | 0.64 |
| C22:2 | 0.61 |
| C22:3a | 0.73 |
| 1H NMR | Ratio TCDD/DMSO (RTD) |
| Total triglycerides | 0.51 |
| Total cholesterol ester | 0.69 |
*Underscore letters indicate isomers (unidentified).
Individual passage number results are in Additional File 1 (Tables S3 and S4).